216 related articles for article (PubMed ID: 31060997)
1. Standard triple therapy in Helicobacter pylori eradication in Turkey: Systematic evaluation and meta-analysis of 10-year studies.
Sezgin O; Aydın MK; Özdemir AA; Kanık AE
Turk J Gastroenterol; 2019 May; 30(5):420-435. PubMed ID: 31060997
[TBL] [Abstract][Full Text] [Related]
2. Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori.
Lim HC; Lee YJ; An B; Lee SW; Lee YC; Moon BS
Helicobacter; 2014 Dec; 19(6):455-61. PubMed ID: 25231089
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia.
Chan CC; Chien NH; Lee CL; Yang YC; Hung CS; Tu TC; Wu CH
BMC Gastroenterol; 2015 Dec; 15():170. PubMed ID: 26635102
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study.
Zagari RM; Bianchi-Porro G; Fiocca R; Gasbarrini G; Roda E; Bazzoli F
Gut; 2007 Apr; 56(4):475-9. PubMed ID: 17028126
[TBL] [Abstract][Full Text] [Related]
5. A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience.
Abd-Elsalam S; Kobtan A; El-Kalla F; Elkhalawany W; Nawasany SE; Saif SA; Yousef M; Ali LA; Soliman S; Mansour L; Habba E; Soliman H; Rizk F; Shehata MA
Medicine (Baltimore); 2016 Jun; 95(24):e3879. PubMed ID: 27310977
[TBL] [Abstract][Full Text] [Related]
6. Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
Zhang D; Ke L; Ni Z; Chen Y; Zhang LH; Zhu SH; Li CJ; Shang L; Liang J; Shi YQ
Medicine (Baltimore); 2017 Aug; 96(32):e7697. PubMed ID: 28796053
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of levofloxacin, amoxicillin and a proton pump inhibitor in the eradication of Helicobacter pylori in Brazilian patients with peptic ulcers.
Silva FM; Queiroz EC; Navarro-Rodriguez T; Barbuti RC; Mattar R; Iriya K; Lee JH; Eisig JN
Clinics (Sao Paulo); 2015 May; 70(5):318-21. PubMed ID: 26039946
[TBL] [Abstract][Full Text] [Related]
8. Triple-drug combination therapy versus six-month proton pump inhibitor monotherapy in non-Helicobacter pylori Helicobacter eradication, and hyperacid environment preference of Helicobacter suis: a clinical study.
Tsukadaira T; Hayashi S; Ota H; Kobayashi N; Agawa H; Kodaira H; Sekiguchi Y; Matsumoto T; Horiuchi K; Negishi T; Tada T
BMC Gastroenterol; 2024 May; 24(1):157. PubMed ID: 38720287
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Helicobacter pylori eradication rates between 7 and 14 days of tailored therapy according to clarithromycin resistance test: A randomized, multicenter, non-inferiority study.
Jung K; Jee SR; Lee MW; Koh M; Kim SJ; Lee J; Park MI
Helicobacter; 2024; 29(3):e13084. PubMed ID: 38717034
[TBL] [Abstract][Full Text] [Related]
10. Fourteen-Day Tegoprazan-Amoxicillin Dual Therapy as the First-Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial.
Kong Q; Mirza IA; Zhang X; Song X; Li X; Zhang Q; Xu L; Guo Y; Yu Y; Zuo X; Li Y; Li Y
Helicobacter; 2024; 29(3):e13098. PubMed ID: 38853394
[TBL] [Abstract][Full Text] [Related]
11. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy.
Kim SE; Park MI; Park SJ; Moon W; Choi YJ; Cheon JH; Kwon HJ; Ku KH; Yoo CH; Kim JH; Lee GW; Song SE
Korean J Intern Med; 2015 Nov; 30(6):801-7. PubMed ID: 26552455
[TBL] [Abstract][Full Text] [Related]
12. Helicobacter pylori eradication with high-dose proton pump inhibitor-amoxicillin dual therapy: A systematic review and meta-analysis.
Yeh JA; Huang HK; Chou AL; Lin HJ; Feng CL; Kuo CJ; Lai CH
Int J Antimicrob Agents; 2024 Jun; 63(6):107159. PubMed ID: 38554984
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Efficacy of 12-day Concomitant Quadruple Therapy versus 14-day High dose Dual Therapy as a First-line
Valizadeh Toosi SM; Feyzi S; Kazemi A
Korean J Gastroenterol; 2024 Apr; 83(4):150-156. PubMed ID: 38659251
[TBL] [Abstract][Full Text] [Related]
14. Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study.
Han YY; Zhou L; Hu YL; Ding XW; Long H; Liu F; Xu M; Zhang ZY; Li SL; Wang QY; Su CX; Chen Y; Chen J; Lin Y; Li PY
J Gastroenterol; 2023 Dec; 58(12):1167-1177. PubMed ID: 37777987
[TBL] [Abstract][Full Text] [Related]
15. High antibiotic resistance rates in Helicobacter pylori strains in Turkey over 20 years: implications for gastric disease treatment.
Sarıkaya B; Çetinkaya RA; Özyiğitoğlu D; Işık SA; Kaplan M; Kırkık D; Görenek L
Eur J Gastroenterol Hepatol; 2024 May; 36(5):545-553. PubMed ID: 38477847
[TBL] [Abstract][Full Text] [Related]
16. Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's disease.
Hashim H; Azmin S; Razlan H; Yahya NW; Tan HJ; Manaf MR; Ibrahim NM
PLoS One; 2014; 9(11):e112330. PubMed ID: 25411976
[TBL] [Abstract][Full Text] [Related]
17. Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials.
Li X; Liu Y; Wang M; Gao L; Liu J; Zhang H; Wu M; Chen H; Lou J; Wang J; Chen J; Geng G; Ma Z; Ding Y
Lancet Infect Dis; 2024 Jun; 24(6):650-664. PubMed ID: 38359854
[TBL] [Abstract][Full Text] [Related]
18. Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: A systematic review and meta-analysis.
Du RC; Hu YX; Ouyang Y; Ling LX; Xu JY; Sa R; Liu XS; Hong JB; Zhu Y; Lu NH; Hu Y
Helicobacter; 2024; 29(1):e13039. PubMed ID: 38036941
[TBL] [Abstract][Full Text] [Related]
19. Vonoprazan-amoxicillin dual therapy with different amoxicillin dosages for treatment-naive patients of Helicobacter pylori infection in China: a prospective, randomized controlled study.
Liu Z; Sun D; Kou L; Jia L; Hao J; Zhou J; Zheng W; Gao F; Chen X
Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):712-719. PubMed ID: 38526917
[TBL] [Abstract][Full Text] [Related]
20. Randomised clinical trial: efficacy and safety of H. pylori eradication treatment with and without Saccharomyces boulardii supplementation.
Sjomina O; Poļaka I; Suhorukova J; Vangravs R; Paršutins S; Knaze V; Park JY; Herrero R; Murillo R; Leja M
Eur J Cancer Prev; 2024 May; 33(3):217-222. PubMed ID: 37942999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
